AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

After rising by over 20% since November, the AstraZeneca (AZN.L) share price is on a good run. And now management has just signed a $1bn deal to acquire EsoBiotec and further secure its long-term ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

Learn More. After rising by over 20% since November, the AstraZeneca (LSE:AZN) share price is on a good run. And now management has just signed a $1bn deal to acquire EsoBiotec and further secure ...

The companies expect the transaction to close during the second quarter of 2025. AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition EsoBiotec SA has entered into a ...

The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune WILMINGTON, Del., March 14, 2025--AstraZeneca and Erin Andrews have teamed up as part of a national public health ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases. Hanmi Pharmaceutical's Global Business ...

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen. The ESG in Life Sciences Summit West is ...